Three years of qualification
Audited Supplier
In This Store
Founded in 1992, Hualan Bio is a national high-tech enterprise which engages in the production, R&D and marketing of plasma products, vaccines, and antibodies, one of the largest manufacturing enterprises of plasma products and vaccines in China. Hualan Bio owns 25 plasma collection stations in China, with steady and enough plasma supply. Hualan Bio’s property is throughout Henan, Chongqing, Beijing and other 6 provinces and cities, and owns 30 subsidiaries. The influenza vaccine had passed GMP of Ukraine, Cote d'Ivoire, WHO-PQ. The plasma products had been exported to India, Peru, Salvador, Paraguay, Pakistan, Belarus, etc. While the vaccines had been exported to Ukraine, Moldova, Albania, Laos, Morocco, Cote d'Ivoire, Mongolia, UNICEF, etc.
Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA.
The contents of services include screening monoclonal antibody, inspection and testing, evaluation, process R&D, drug analysis, preparation development, production approval application, filling and packaging, labeling, etc.
Year of Establishment: 1992
Total Assets(USD):
Total Number of Staff:
Main Competitive Advantages: International Approvals/Standards,Experienced R&D Staff,Delivery Term,Large Product Line,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages: Plasma products: Surgical Lyophilized Fibrin Sealant, Human, Human Coagulation Factor VIII, Human Albumin, Human Fibrinogen, Human Hepatitis B Immunoglobulin, Human Tetanus Immunoglobulin, Human Prothrombin Complex, Human Immunoglobulin, Human Thrombin, Lyophilized for External Use, Human Rabies Immunoglobulin, Human Immunoglobulin (pH4) for Intravenous Injection； Vaccine products: Meningococcal Polysaccharide Vaccine Group ACYW135, Influenza Vaccine (Split Virion), Inactivated, Recombinant Hepatitis B Vaccine (Hansenula polymorpha), Influenza A (H1N1) Vaccine, (Split, Inactivated), Influenza Vaccine(Split Virion), Inactivated，Quadrivalent, Group A and C Meningococcal Polysaccharide Vaccine; R&D and production of monoclonal antibody products: Recombinant anti-CTL-4 human monoclonal antibody injection, Injection of Recombinant Anti-RANKL Whole Human Monoclonal Antibody Injection, Recombinant anti-Vectibix endothelial growth factor (EGFR) monoclonal antibody injection, Recombinant human anti-tumor necrosis factor (TNFα) monoclonal antibody injection, Injection-use recombinant anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody, Recombinant anti-vascular endothelial growth factor (VEGF) monoclonal antibody injection, Recombinant anti-lymphoma (CD20) monoclonal antibody injection; Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA. The contents of services include screening monoclonal antibody, inspection and testing, evaluation, process R&D, drug analysis, preparation development, production approval application, filling and packaging, labeling, etc.
Patents and Copyrights: Self developed chromatography process and critical media, possesses independent intellectual property of affinity chromatography, separation and purification technology on specific immunoglobulin, ensuring high purity of extracted products and increasing the output.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go
